201 results
DEFM14A
IMGN
Immunogen, Inc.
2 Jan 24
Proxy related to merger
4:26pm
of a debt commitment letter.
On November 28, 2023, representatives of Party A informed representatives of Lazard that, while Party A remained highly … , and an executed debt commitment letter (the “Party B November 29 Proposal”). Among other changes, Party B’s revised merger agreement draft rejected any
PREM14A
IMGN
Immunogen, Inc.
21 Dec 23
Preliminary proxy related to merger
4:52pm
of a debt commitment letter.
On November 28, 2023, representatives of Party A informed representatives of Lazard that, while Party A remained highly … , and an executed debt commitment letter (the “Party B November 29 Proposal”). Among other changes, Party B’s revised merger agreement draft rejected any
DEFA14A
IMGN
Immunogen, Inc.
21 Dec 23
Additional proxy soliciting materials
3:54pm
. This commitment will extend for one year following the closing of the merger.
Is there an impact on our Employee Stock Purchase Plan (ESPP)? What happens … as employee benefits that are at least as favorable in the aggregate as those benefits provided at closing and that this commitment will extend for the period
DEFA14A
IMGN
Immunogen, Inc.
30 Nov 23
Additional proxy soliciting materials
4:08pm
and our future potential to deliver more good days to people living with cancer.
This transaction is the culmination of our 40-year commitment … as the benefits provided to you at closing. This commitment will extend for the period of one year following the closing of the merger.
All employment
DEFA14A
EX-99.1
IMGN
Immunogen, Inc.
30 Nov 23
Additional proxy soliciting materials
4:07pm
conditions.
"The acquisition of ImmunoGen demonstrates our commitment to deliver on our long-term growth strategy and enables AbbVie to further diversify … is an exciting opportunity for the combined companies to advance innovation in ADCs. This transaction is the culmination of our 40-year commitment
DEFA14A
EX-2.1
orqqsr bga
30 Nov 23
Additional proxy soliciting materials
4:07pm
8-K
EX-2.1
c2pq qx6sz5ws
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
8-K
EX-99.1
khgz6hecvtxj7nxes
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
8-K
EX-99.1
98rsjy99pww
2 Nov 23
ImmunoGen Reports Recent Progress and Third Quarter 2023 Financial Results
6:35am
8-K
EX-99.1
2r7bp0ans1jxtds
18 Sep 23
ImmunoGen Appoints Lauren White as Senior Vice President and Chief Financial Officer
6:35am
8-K
EX-99.1
1v7076 f7jiy
31 Jul 23
ImmunoGen Reports Recent Progress and Second Quarter 2023 Financial Results
6:40am
8-K
EX-1.1
5e84om fjjgult3alm8
5 May 23
Entry into a Material Definitive Agreement
5:15pm
424B5
2n9b hjn5fricx35dju4
5 May 23
Prospectus supplement for primary offering
4:49pm
424B5
4h7neyomom
3 May 23
Prospectus supplement for primary offering
4:05pm
8-K
EX-99.1
apcjzhjxv2ux0a
3 May 23
ELAHERE® Demonstrates Overall Survival Benefit in the Phase 3 MIRASOL Trial in Patients with FRα-Positive Platinum-Resistant Ovarian Cancer
6:35am
8-K
EX-99.1
o4nrcl eb2d7lrdyak6
28 Apr 23
ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results
6:36am